Malta - angličtina - Medicines Authority

actavis group ptc ehf revkjavikurvegi 76-78, 220 hafnarfjordur, iceland - etoricoxib - film-coated tablet - etoricoxib 30 mg - antiinflammatory and antirheumatic products

Malta - angličtina - Medicines Authority

johnson & johnson (ireland) limited airton road tallaght, dublin 24, dublin, ireland - ibuprofen, pseudoephedrine hydrochloride - film-coated tablet - ibuprofen 200 mg pseudoephedrine hydrochloride 30 mg - cough and cold preparations

Malta - angličtina - Medicines Authority

accord healthcare limited - ibuprofen - film-coated tablet - ibuprofen 600 mg - antiinflammatory and antirheumatic products

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - ibuprofen ph. eur. - film-coated tablet - 200 milligram(s) - propionic acid derivatives; ibuprofen

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - ibuprofen ph. eur. - film-coated tablet - 400 milligram(s) - propionic acid derivatives; ibuprofen

Singapur - angličtina - HSA (Health Sciences Authority)

pfizer private limited - voriconazole - tablet, film coated - 200 mg - voriconazole 200 mg

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - voriconazole, quantity: 200 mg - tablet, film coated - excipient ingredients: lactose monohydrate; pregelatinised maize starch; maize starch; croscarmellose sodium; povidone; silicon dioxide; magnesium stearate; titanium dioxide; hypromellose; triacetin - voriconazole is indicated for treatment of the following fungal infections:invasive aspergillosis. serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia). serious fungal infections caused by scedosporium spp and fusarium spp. other serious fungal infections, in patients intolerant of, or refractory to, other therapy. prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - voriconazole, quantity: 50 mg - tablet, film coated - excipient ingredients: povidone; croscarmellose sodium; lactose monohydrate; magnesium stearate; pregelatinised maize starch; titanium dioxide; hypromellose; triacetin - voriconazole sandoz is indicated for treatment of the following fungal infections:,- invasive aspergillosis.,- serious candida infections (including c. krusei), including oesophageal and systemic candida infections (hepatosplenic candidiasis, disseminated candidiasis, candidaemia).,- serious fungal infections caused by scedosporium spp and fusarium spp.,- other serious fungal infections, in patients intolerant of, or refractory to, other therapy,- prophylaxis in patients who are at high risk of developing invasive fungal infections. the indication is based on studies including patients undergoing haematopoietic stem cell transplantation.,- this brand is only available as tablets and therefore only indicated for adults and children 12 years or older who can tolerate tablets. for dosing requirements for populations who require intravenous or oral suspension treatment see dosage and administration.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

astrazeneca pty ltd - ticagrelor, quantity: 90 mg - tablet, film coated - excipient ingredients: hyprolose; purified talc; iron oxide yellow; macrogol 400; hypromellose; mannitol; calcium hydrogen phosphate dihydrate; titanium dioxide; magnesium stearate; sodium starch glycollate type a - brilinta, in combination with aspirin, is indicated for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction and stroke) in adult patients with acute coronary syndromes (unstable angina [ua], non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]) including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - codeine phosphate hemihydrate, quantity: 12.8 mg; ibuprofen, quantity: 200 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; croscarmellose sodium; pregelatinised maize starch; microcrystalline cellulose; titanium dioxide; hypromellose; macrogol 400 - for temporary relief of acute moderate pain and inflammation in patients over the age of 12 years